Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program

Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY

October 19, 2015 6:42 AM EDT

Oppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00), following the company's Oct. 15th announcement of a licensing agreement for FPA008 with BMY. FPRX will receive $350M cash upfront and is eligible for an additional $1.39B in development/regulatory... More

Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY

October 15, 2015 4:06 PM EDT

Leerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More

Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)

October 15, 2015 9:20 AM EDT

Five Prime Therapeutics, Inc.(Nasdaq: FPRX) shares are ripping early following news that the company entered an... More